Injectable Depot Medroxy Progesterone Acetate: A Safe Contraceptive Choice in Public Health System of India

Vikas Gupta, Suraj Chawla, Pawan K. Goel

Abstract


India was the first country in the world to launch a family planning programme, as early as 1952, with the main aim of controlling its population. India’s population has already reached 1.26 billion and considering the high decadal growth rate of 17.64, the country’s population is slated to surpass that of China by 2028.

Keywords


Depot Medroxy Progesterone Acetate; Public Health System; India

Full Text:

PDF

References


Department of Health and Family Welfare. Reference Manual

for Injectable Contraceptive (DMPA). New Delhi. Ministry of

Health and Family Welfare; 2016.

Ahmed S, Li Q, Liu L, Tsui AM. Maternal deaths averted by

contraceptive use: An analysis of 172 countries. Lancet 2012;380:111‑25.

Population Foundation India. Evidences on Contraceptive Method Mix

in developing countries: South/South‑East Asia. New Delhi: PFI; 2016.

Srivastava RK, Tanwar H, Singh P, Patro BC. Injectable Contraceptives

to Expand the Basket of Choice under Family Planning Programme:

An Update. New Delhi. Ministry of Health and Family Welfare; 2012.

Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive

efficacy and safety of DMPASC. Contraception 2004;70:269‑75.

Association of Reproductive Health Professionals. Choosing a birth

control method: Injectables. Available from: https://www.arhp.org/

Publications‑and‑Resources/Quick‑Reference-Guide‑for‑Clinicians/

choosing/Injectable. [Last accessed on 2019 Feb 20].

Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in

bleeding patterns with depot medroxyprogesterone acetate

subcutaneous injection 104 mg. Contraception 2006;74:234‑8.

Kaunitz AM, Arias R, McClung M. Bone density recovery after

depot medroxyprogesterone acetate injectable contraception use.

Jain A, Winfrey W. Contribution of contraceptive discontinuation

to unintended births in 36 developing countries. Stud Fam Plann

;48:269‑78.

Burke HM, Mueller MP, Perry B, Packer C, Bufumbo L,

Mbengue D. Observational study of the acceptability of Sayana®

Press among intramuscular DMPA users in Uganda and Senegal.

Contraception 2014;89:361‑7.

Polis C, Nakigozi GF, Nakawooya H, Mondo G, Makumbi F,

Gray RH. Preference for Sayana® Press versus intramuscular

Depo‑Provera among HIV‑positive women in Rakai, Uganda:

A randomized crossover trial. Contraception 2013;89:385‑95.

Curry L, Taylor L, Pallas SW, Cherlin E, Pérez‑Escamilla R,

Bradley EH. Scaling up depot medroxyprogesterone acetate (DMPA):

A systematic literature review illustrating the AIDED model. Reprod

Health 2013;10:39.

International Institute for Population Sciences. National Family

Health Survey (NFHS‑4), 2015–16: India: Volume I. Mumbai,

India: IIPS; 2017. Available from: http://www.rchiips.org/nfhs/

report.shtml. [Last accessed on 2019 Aug 11].

Contraception 2008;77:67‑76.

Polis CB, Curtis KM, Hannaford PC, Phillips SJ, Chipato T,

Kiarie JN, et al. An updated systematic review of

epidemiological evidence on hormonal contraceptive methods

and HIV acquisition in women. AIDS 2016;30:2665‑83.

Cole K, Saad A. The coming‑of‑age of subcutaneous injectable

contraception. Glob Health Sci Pract 2018;6:1‑5.

Hofmeyr GJ, Morrison CS, Baeten JM, Chipato T, Donnell D,

Gichangi P, et al. Rationale and design of a multi‑center, open label,

randomised clinical trial comparing HIV incidence and contraceptive

benefits in women using three commonly‑used contraceptive

methods (the ECHO study). Gates Open Res 2017;1:17.

Jain AK. Hormonal contraception and HIV acquisition

risk: Implications for individual users and public policies.

Contraception 2012;86:645‑52.

Jain AK, Obare F, RamaRao S, Akew I. Reducing unmet need

by supporting women with met need. Int Perspect Sex Reprod

Health 2013;39:133‑41.